The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
40 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $7,464,757 in first-year total cost, median $201,623.
Most frequent study sections
- Developmental Therapeutics Study Section[DT]8
- Special Emphasis Panel[ZRG1 BMCT-C (01)]7
- Cancer Genetics Study Section[CG]4
- Chemo/Dietary Prevention Study Section[CDP]3
- Drug Discovery and Molecular Pharmacology Study Section[DMP]3
Most frequent institutions
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO4
- THOMAS JEFFERSON UNIVERSITY3
- STANFORD UNIVERSITY2
- STATE UNIVERSITY NEW YORK STONY BROOK2
- UNIVERSITY OF ALABAMA AT BIRMINGHAM2
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2015 | Targeting Pancreatic Cancer with Novel Mnk-eIF4E and AR Modulating Agents1R21CA195694-01 | NJAR, VINCENT COLLINS OFUKA | UNIVERSITY OF MARYLAND BALTIMORE, MD | $215,284 | DMP |
| 2015 | Deciphering SIRT6-dependent metabolic liabilities in Pancreatic cancer1R21CA198109-01 | MOSTOSLAVSKY, RAUL | MASSACHUSETTS GENERAL HOSPITAL, MA | $214,146 | TCB |
| 2015 | New transgenic animal model to study pancreatic cancer1R21CA191515-01 | FISHER, PAUL B | VIRGINIA COMMONWEALTH UNIVERSITY, VA | $213,881 | DT |
| 2015 | Somatic Engineering-based Models of Pancreatic Cancer1R21CA194910-01 | WINSLOW, MONTE MEIER | STANFORD UNIVERSITY, CA | $212,580 | CG |
| 2015 | Aptamers as Proteomic Tools for Pancreatic Cancer Biomarker Identification1R21CA198287-01 | WHITE, REBEKAH | DUKE UNIVERSITY, NC | $207,495 | CBSS |
| 2015 | Dual recombinase models of pancreatic cancer1R21CA191631-01 | SEELEY, ELLIOTT SCOTT | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $206,516 | ZRG1 |
| 2015 | Pancreatic cancer control by a novel combination treatment1R21CA175699-01A1 | MACKENZIE, GERARDO GUILLERMO | STATE UNIVERSITY NEW YORK STONY BROOK, NY | $206,190 | DT |
| 2015 | Two phospho-compounds for pancreatic cancer prevention1R21CA185209-01A1 | MACKENZIE, GERARDO GUILLERMO | STATE UNIVERSITY NEW YORK STONY BROOK, NY | $206,190 | CDP |
| 2015 | A new energy restriction mimetic that targets pancreatic cancer1R21CA185276-01A1 | LANZA-JACOBY, SUSAN PATRICIA | THOMAS JEFFERSON UNIVERSITY, PA | $203,580 | CDP |
| 2015 | Preclinical Validation of U1 Adaptors for Suppression of KRAS in Pancreatic Cancer1R21CA191622-01 | CARPIZO, DARREN RICHARDGUNDERSON, SAMUEL I | RUTGERS, THE STATE UNIV OF N.J., NJ | $203,337 | DMP |
| 2015 | Therapeutic Monitoring in Pancreatic Cancer Using an Exosome Based Mass Spec Assay1R21CA189775-01A1 | LUBMAN, DAVID M. | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $202,438 | ZRG1 |
| 2015 | A novel mouse model to identify biomarkers of IPMN formation and progression1R21CA194839-01 | SANDER, MAIKE | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $202,275 | TCB |
| 2015 | Identifying new drug targets to block K-Ras/Raf in pancreatic cancer.1R21CA191392-01 | STORK, PHILIP J.S. | OREGON HEALTH & SCIENCE UNIVERSITY, OR | $200,970 | ZRG1 |
| 2015 | High fat diet stimulates pancreatic cancer through the actions of Cholecystokinin1R21CA194745-01A1 | SMITH, JILL P | GEORGETOWN UNIVERSITY, DC | $200,429 | CDP |
| 2015 | Targeting PAK4 for Overcoming Drug Resistance in Pancreatic Cancer1R21CA188818-01A1 | AZMI, ASFAR SMOHAMMAD, RAMZI M. | WAYNE STATE UNIVERSITY, MI | $199,285 | DT |
| 2015 | Targeting DCLK1 kinase activity in pancreatic cancer1R21CA186175-01A1 | HOUCHEN, COURTNEY WAYNE | UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR, OK | $193,140 | DT |
| 2015 | Glycan control of stem cell-associated pathways in pancreatic cancer1R21CA192629-01 | BELLIS, SUSAN L | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $191,835 | TPM |
| 2015 | Targeting Kras in Pancreatic Cancer1R21CA199050-01 | LOPEZ-BERESTEIN, GABRIELMAITRA, ANIRBANOZPOLAT, BULENT | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $174,000 | ZRG1 |
| 2015 | Non-invasive Differentiation of Benign Lesions from Aggressive Pancreatic Cancer1R21CA185689-01A1 | CRAIK, CHARLES SCOTTKIRKWOOD, KIMBERLY SAUNDERS | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $172,097 | CMIP |
| 2015 | A Creative Integration of Omega-3 Fatty Acids into Pancreatic Cancer Chemotherapy1R21CA179362-01A1 | CUI, ZHENGRONG | UNIVERSITY OF TEXAS AT AUSTIN, TX | $168,563 | DT |
| 2015 | IGF-II-Based Approach to Therapy for Pancreatic Cancer1R21CA198292-01 | MACDONALD, RICHARD G. | UNIVERSITY OF NEBRASKA MEDICAL CENTER, NE | $163,010 | DT |
| 2015 | Regulation of pancreatic ductal adenocarcinoma progression by Hnf4a1R21CA194764-01 | SNYDER, ERIC LEE | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $40,881 | MONC |
| 2015 | Treating pancreatic cancer with Listeria-32P1R21CA199010-01 | GRAVEKAMP, CLAUDIA | ALBERT EINSTEIN COLLEGE OF MEDICINE, NY | $19,682 | RTB |
| 2014 | ERK inhibitor resistance and ERK isoform-dependent growth in pancreatic cancer1R21CA179193-01A1 | DER, CHANNING J. | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $231,887 | CG |
| 2014 | Investigation of therapeutic modulators of apoptotic priming in pancreatic cancer1R21CA188858-01 | LETAI, ANTHONY G | DANA-FARBER CANCER INST, MA | $225,765 | DMP |
| 2014 | An inhibitor of multiple anti-apoptotic gene products for pancreatic cancer1R21CA180764-01A1 | LI, FENGZHI | ROSWELL PARK CANCER INSTITUTE CORP, NY | $221,589 | DT |
| 2014 | Targeting Cell Surface GRP78 as a Novel Therapy for Pancreatic Cancer1R21CA179273-01A1 | LEE, AMY S | UNIVERSITY OF SOUTHERN CALIFORNIA, CA | $214,564 | ZRG1 |
| 2014 | Multiplexed in vivo drug screening: Inhibitors of metastatic seeding1R21CA188863-01 | BOGYO, MATTHEWWINSLOW, MONTE MEIER | STANFORD UNIVERSITY, CA | $209,745 | TPM |
| 2014 | Preclinical evaluation of a targeted Bmi1 inhibitor in pancreatic cancer1R21CA188857-01 | OLIVE, KENNETH P. | COLUMBIA UNIVERSITY HEALTH SCIENCES, NY | $206,431 | DT |
| 2014 | Utilizing HuR to optimize the treatment of pancreatic cancer1R21CA182692-01A1 | BRODY, JONATHAN | THOMAS JEFFERSON UNIVERSITY, PA | $202,275 | CONC |
| 2014 | GPCRs: novel targets in cancer-associated fibroblasts1R21CA189477-01 | INSEL, PAUL ALOWY, ANDREW M | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $202,275 | MIST |
| 2014 | Directional Motility and ERM Scaffolding in Pathfinder Pancreatic Carcinoma Cells1R21CA176364-01A1 | MULDER, KATHLEEN M | PENNSYLVANIA STATE UNIV HERSHEY MED CTR, PA | $199,665 | ZRG1 |
| 2014 | Characterization of Drug Survival by Pancreatic Cancer Cells in vitro and in vivo1R21CA182651-01A1 | YEN, TIMOTHY | RESEARCH INST OF FOX CHASE CAN CTR, PA | $194,119 | ZRG1 |
| 2014 | Therapy of pancreatic cancer with 212Pb-labeled B7-H3 specific Ab and LDE2251R21CA173120-01A1 | BUCHSBAUM, DONALD JFERRONE, SOLDANO | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $186,047 | RTB |
| 2014 | Adaptable hydrogel platform to study pancreatic cancer1R21CA188911-01 | LIN, CHIEN-CHI | INDIANA UNIVERSITY INDIANAPOLIS, IN | $169,650 | BMBI |
| 2014 | N-cadherin and Metastatic Dissemination1R21CA176097-01A1 | RADICE, GLENN LAWRENCE | THOMAS JEFFERSON UNIVERSITY, PA | $168,563 | TPM |
| 2014 | Elucidating and targeting epigenetic oncogenic networks in pancreatic cancer1R21CA182662-01 | TZATSOS, ALEXANDROS | GEORGE WASHINGTON UNIVERSITY, DC | $167,480 | CG |
| 2014 | Phosphorylated Form of Activated IKKbeta and Pancreatic Cancer1R21CA182820-01 | NATARAJAN, AMARNATH (AMAR) | UNIVERSITY OF NEBRASKA MEDICAL CENTER, NE | $163,669 | ZRG1 |
| 2014 | A Genetically Defined System to Identify Factors Essential for KRas Oncogenesis1R21CA176561-01A1 | COLLISSON, ERIC | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $159,818 | CG |
| 2014 | TARGETING CCR2 TO OVERCOME IMMUNOSUPPRESSION AND IMPROVE IMMUNOTHERAPY1R21CA182701-01A1 | DENARDO, DAVID G | WASHINGTON UNIVERSITY, MO | $123,411 | CII |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.